Vale (VALE) Gears Up to Report Q3 Earnings: What’s in Store?


Vale S.A


VALE

is scheduled to report third-quarter 2020 results on Oct 28, after the closing bell.

Q2 Results

Vale’s second-quarter earnings were flat year over year while revenues declined compared with the year-ago quarter. Meanwhile sales beat the Zacks Consensus Estimate, earnings missed the same.

Q3 Estimates

The Zacks Consensus Estimate for third-quarter total sales is pegged at $10.8 billion, indicating growth of 6% from the year-ago quarter. The consensus mark for earnings currently stands at 72 cents, suggesting growth of 100% from the prior-year quarter. The estimate has gone down 11% over the past seven days.

The company has a trailing four-quarter negative earnings surprise of 7.7%, on average.

VALE S.A. Price and EPS Surprise

VALE S.A. Price and EPS Surprise


VALE S.A. price-eps-surprise

|

VALE S.A. Quote

Factors to Note

Vale recently provided third-quarter-2020 production update, which offered a sneak peek as to how the company is likely to fare in the to-be-reported quarter. Iron ore production increased 31% sequentially to 88.7 Mt in the quarter. The company attained a production record of 56.9 Mt in the third quarter in the Northern System, primarily driven by the S11D mine. In the Southern and Southeastern Systems, overall performance improved across operating units, particularly in the Itabira Complex and Timbopeba site.

Pellets production was 8.6 Mt in the reported quarter, reflecting a sequential rise of 21%. Sales volumes of iron ore fines and pellets were 74.2 Mt in the quarter, up 21% from the second quarter.

Iron ore prices have been rallying in the third quarter and gained around 30% year to date. Demand for the primary steelmaking commodity has increased on strong demand from China as steel production has gained steam in the country driven by its efforts to recover from the coronavirus-induced shutdown. This combined with persistent concerns over a supply shortage from Brazil, which has been hit hard by the COVID-19 pandemic, fueled the rally in iron ore prices. Higher iron production and rising iron prices are likely to have benefited the company’s performance in the quarter to be reported.

Vale has been focusing on maintaining its ‘”value over volume” approach for the iron ore business. The company remains committed to delivering the highest possible margins by managing extensive supply chain and flexible product portfolio. The company has also been focusing on controlling costs. These efforts may get reflected in the third-quarter results.

What Does Our Model Say?

Our proven model does not conclusively predict an earnings beat for Vale this time around. The combination of a positive

Earnings ESP

and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of beating estimates.

You can uncover the best stocks to buy or sell before they’re reported with our

Earnings ESP Filter

.


Earnings ESP:

The Earnings ESP for Vale is 0.00%.


Zacks Rank:

The company currently carries a Zacks Rank of 2.

Price Performance

In a year’s time, shares Vale have declined 2.7%, in line with the

industry

.

Stocks to Consider

Here are some Basic Material stocks, which you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases:


Newmont Corporation


NEM

has an Earnings ESP of +2.24% and a Zacks Rank of 1, currently. You can see


the complete list of today’s Zacks #1 Rank stocks here


.


Cabot Corporation


CBT

, currently a Zacks #2 Ranked stock, has an Earnings ESP of +12.50%.


Eastman Chemical Company


EMN

has a Zacks Rank #2 and an Earnings ESP of +3.46%, at present.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.



See these 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.

Click to get this free report


To read this article on Zacks.com click here.


Zacks Investment Research